AstraZeneca reports full results from the Bax24 phase III study. Read more. AstraZeneca also enters into a new collaboration with the government, Scania and RISE around green technology. Read more.
Attana Strengthens customer collaborations with the re-recruitment of an experienced application specialist. Read more.
BioInvent presents BI-1910 data validating TNFR2 as a novel target for immunotherapy of advanced solid tumors with phase 1 data at SITC 2025. Read more.
C-ROW has completed a share buyback during week 45, 2025. Read more.
Camurus reports positive results for CAM2056, semaglutide monthly depot. Read more.
Cereno Scientific submits study protocol for phase IIb study with CS1 in pulmonary arterial hypertension (PAH) to the US FDA. Read more.
Cinclus Pharma sponsors scientific abstract for conference highlighting the clinical and economic costs of failed PPI treatments in severe erosive GERD. Read more.
Egetis Therapeutics is subject to technical analysis in Dagens Börs. Read more.
Lytix Biopharma presents new Phase II study data from partners at SITC 2025 that further validates the unique immune-activating mechanism of ruxotemitide. Read more.
Novo Nordisk announces that the company will not increase its bid to acquire Metsera. Read more.
Redsense Medical begins sales activities in Australia following TGA approval of Redsense Clamp. Read more.
SensoDetect advances its expansion in the Middle East and introduces strategy for screening programs at private schools as well as SensoDetect-owned screening centers. Read more.
SOBI presents clinically relevant results from a pivotal study of olezarsen in patients with sHTG as a late-breaker at the AHA Scientific Sessions. Read more.
Spago Nanomedical announces that the subscription period in the company's rights issue begins today. Read more.
SpectraCure reports continued promising results in the study for primary localized prostate cancer. Read more.
Stayble Therapeutics provides an update on the company's intangible assets with approved patents in a large number of countries. Read more.
Vivesto reports positive interim results for Paccal Vet pilot study in dogs. Read more.
Xintela carries out a rights issue of shares of approximately SEK 72,8 million and raises a loan of SEK 20 million. Read more.
Zenicor Medical Systems The rights issue is now 100 percent secured through an expanded top guarantee commitment. Read more.
Insider trading & whistleblowing
Ambi Bavarian Nordic Biohit ChemoMetec Gubra Medistim
Invitations & presentations
Summons
Reports
Arctic Bioscience BiBBInstruments
Nomination committees
The latest from BioStock
» BiBBInstruments off the starting blocks for its U.S. launch
» ESMO 2025: mRNA vaccine boosts checkpoint inhibitors
» Empros Pharma presents positive topline results for EMP16
» The generalists about to jump on the bandwagon
» BioPorto advances kidney study and sharpens strategic direction
» Thor Medical comments on the Telix agreement